Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|September 10, 2015
Source BioScience and Oxford Gene Technology Collaborate to Deliver Next-Generation Sequencing Service
Author(s)Pharmaceutical Technology Editors
Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio.
Advertisement
Source BioScience
Nick Ash, CEO of Source BioScience commented in a press statement that the company has forged a strong relationship with OGT and worked together on several projects. Ash said that with this acquisition, customers can now benefit from laboratory services from Source BioScience in conjunction with OGT’s analysis software.
According to Mike Evans, CEO of OGT, the company’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the genetic analysis that OGT provides.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement